Non-ST-elevation myocardial infarction: Difference between revisions
| Line 32: | Line 32: | ||
==Treatment== | ==Treatment== | ||
===Anti-ischemia=== | |||
#Oxygen | |||
##ACC recs O2 for sats <90% (evidence indeterminant) | |||
#Nitrates | |||
##No mortality benefit | |||
##Dilates coronary arts, decr preload, slight decr afterload | |||
##Use of viagra within 24hr can lead to profound and prolonged vasodilation (and death) | |||
##B-block to avoid reflex tachycardia | |||
#B-Blockers | |||
##Goal HR is 50-60 | |||
##Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms | |||
##(Decreases progression from UA to MI by 13% | |||
##Decr inotropic and chronotropic response to catechols | |||
##use dilt or verap if can't use b-block (nifedipine clearly harmful) | |||
##No IV BB in ED, PO within 24 H | |||
#ACE Inhibitor | |||
##start short-acting (captopril) w/in 24hr of admission | |||
##Reduces RR of 30 day mort by 7% | |||
##Those w/ recent MI (esp ant) and LV dysfunction benefit most | |||
#Transfusion | |||
##Transfuse to keep Hb>10 | |||
#Magnesium | |||
##may use if pain after 3 doses of NTG | |||
##Reduces pain and theoretically can decr HR and SBP and O2 demand | |||
##Use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts) | |||
===Antiplatelet=== | |||
#ASA | |||
##Rec dose is 160-325mg chewed | |||
##Reduces death from MI by 12.5-6.4% | |||
##Should be used in all ACS unless contraindicated | |||
#Clopidogrel (plavix 300mg po then 75qd) | |||
##In addition to ASA | |||
##Used over ticlopidine b/c faster onset & less s/e | |||
##Mortality benifit with NSTEMI | |||
##Main risk and contraind is bleeding | |||
##CURE trial showed decr in CV death, MI or stroke by 9.3-11.5% | |||
#GPIIb/IIIa(-) = Eptifibatide (Integrillin) | |||
##High-risk pts benefit most | |||
###PURSUIT trial found 30 day death or MI decr from 15.7% to 14.2% | |||
##Incr ICH not seen w/ use | |||
##Benefit if early PCI is planned; ? to no benefit if PCI not planned | |||
##Reserved (if no pci) for positive trop or isch/ecg changes despite ASA, lovenox, b-block etc | |||
===Antithombotics=== | |||
#Class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa | |||
#Unfractionated Heparin | |||
##Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s | |||
#LMWH: Enoxaparin (lovenox) | |||
##1mg/kg sc BID | |||
##Safer (ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH) | |||
##AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hr | |||
##Adjust for CrCl<30ml and extremes of weight | |||
##No need to monitor labs | |||
#Hirudin is approved only for pts w/ HIT | |||
===Thrombolytics=== | |||
#Only useful for STEMI | |||
# | ===Angiography=== | ||
#Indicated for: | |||
##Recurrent angina/ischemia w/ or w/o sx of CHF | ##Recurrent angina/ischemia w/ or w/o sx of CHF | ||
##Elevated troponins | ##Elevated troponins | ||
Revision as of 19:40, 14 May 2011
Background
- 33% w/ confirmed MI have no CP on presentation (esp older, female, DM, CHF)
- 5% of NSTEMI will develop cardiogenic shock (60% mortality)
- Age >65 w/ MI and anemia had 33% reduction in 30 day mort if transfused to keep HCT >30
- Association between quantity of troponin and risk of death
Diagnosis
- ACS = STEMI, NSTEMI, UA
- Angina is considered unstable with 1 or more:
- Occurs for 1st time
- Occurs at rest
- Accelerating frequency or severity
- ECG is normal in 8% of all confirmed MI's
- Intensity of Rx should be based on likelihood that sx are due to acute coronary thombosis
TIMI RISK STRATIFICATION SCORE
- 1 point for each
- Age ≥65 years
- Presence of at least three risk factors for CHD
- Prior coronary stenosis of ≥50 percent
- Presence of ST segment deviation on admission ECG
- At least two anginal episodes in prior 24 hours
- Elevated serum cardiac biomarkers
- Use of aspirin in prior seven days
- Likelihood of mortality, new or recurrent MI, or require revascularization at 14 days
- Score of 0/1 - 4.7 percent
- Score of 2 - 8.3 percent
- Score of 3 - 13.2 percent
- Score of 4 - 19.9 percent
- Score of 5 - 26.2 percent
- Score of 6/7 - 40.9 percent
Treatment
Anti-ischemia
- Oxygen
- ACC recs O2 for sats <90% (evidence indeterminant)
- Nitrates
- No mortality benefit
- Dilates coronary arts, decr preload, slight decr afterload
- Use of viagra within 24hr can lead to profound and prolonged vasodilation (and death)
- B-block to avoid reflex tachycardia
- B-Blockers
- Goal HR is 50-60
- Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms
- (Decreases progression from UA to MI by 13%
- Decr inotropic and chronotropic response to catechols
- use dilt or verap if can't use b-block (nifedipine clearly harmful)
- No IV BB in ED, PO within 24 H
- ACE Inhibitor
- start short-acting (captopril) w/in 24hr of admission
- Reduces RR of 30 day mort by 7%
- Those w/ recent MI (esp ant) and LV dysfunction benefit most
- Transfusion
- Transfuse to keep Hb>10
- Magnesium
- may use if pain after 3 doses of NTG
- Reduces pain and theoretically can decr HR and SBP and O2 demand
- Use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts)
Antiplatelet
- ASA
- Rec dose is 160-325mg chewed
- Reduces death from MI by 12.5-6.4%
- Should be used in all ACS unless contraindicated
- Clopidogrel (plavix 300mg po then 75qd)
- In addition to ASA
- Used over ticlopidine b/c faster onset & less s/e
- Mortality benifit with NSTEMI
- Main risk and contraind is bleeding
- CURE trial showed decr in CV death, MI or stroke by 9.3-11.5%
- GPIIb/IIIa(-) = Eptifibatide (Integrillin)
- High-risk pts benefit most
- PURSUIT trial found 30 day death or MI decr from 15.7% to 14.2%
- Incr ICH not seen w/ use
- Benefit if early PCI is planned; ? to no benefit if PCI not planned
- Reserved (if no pci) for positive trop or isch/ecg changes despite ASA, lovenox, b-block etc
- High-risk pts benefit most
Antithombotics
- Class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa
- Unfractionated Heparin
- Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s
- LMWH: Enoxaparin (lovenox)
- 1mg/kg sc BID
- Safer (ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH)
- AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hr
- Adjust for CrCl<30ml and extremes of weight
- No need to monitor labs
- Hirudin is approved only for pts w/ HIT
Thrombolytics
- Only useful for STEMI
Angiography
- Indicated for:
- Recurrent angina/ischemia w/ or w/o sx of CHF
- Elevated troponins
- New or presumably new ST-segment depression
- High-risk findings on noninvasive stress testing
- Depressed LV function
- Hemodynamic instability
- Sustained V-tach
- PCI w/in previous 6 mo
- Prior CABG
See Also
Cards: Cocaine CP
Source
EM Practice
UpToDate
